Comparison · NCT03573505-sae
BG00011 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. BG00011 vs Placebo: serious adverse events. Trial comparisons, record NCT03573505-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03573505-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.278 | 0.176 | 0.409 | wilson | |
| Risk in group 2 | 0.135 | 0.0668 | 0.253 | wilson | |
| Risk difference, group 1 minus group 2 | 0.143 | -0.0126 | 0.291 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.06 | 0.916 | 4.65 | log | |
| Odds ratio, group 1 over group 2 | 2.47 | 0.915 | 6.68 | log | |
| Number needed to harm, for one more participant with a serious adverse event on BG00011 than on Placebo | 6.99 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | BG00011 | Participants received BG00011 56 milligram (mg), once weekly by SC injection up to a maximum of 46 weeks. Median exposure to BG00011 was 17.14 weeks. | 15 | 54 | EG001 |
| Group 2 | Placebo | Participants received BG00011-matching placebo, once weekly by subcutaneous (SC) injection up to a maximum of 46 weeks. Median exposure to placebo was 19.14 weeks. | 7 | 52 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 60 Weeks (End of Study)
Source ClinicalTrials.gov
Trial
- Title
- An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
- NCT number
- NCT03573505
- Phases
- PHASE2
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BG00011, Placebo
- Lead sponsor
- Biogen
- Results first posted
- 2020-11-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03573505?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03573505-sae